Tait DRHatherill MVan Der Meeren OGinsberg AMVan Brakel ESalaun BScriba TJAkite EJAyles HMBollaerts ADemoitié MADiacon AEvans TGGillard PHellström EInnes JCLempicki MMalahleha MMartinson NMesia Vela DMuyoyeta MNduba VPascal TGTameris MThienemann FWilkinson RJRoman F2025-05-232019-Dec-110.1056/NEJMoa1909953https://pubs.cidrz.org/handle/123456789/10442BACKGROUND: Results of an earlier analysis of a trial of the M72/AS01 METHODS: From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with RESULTS: A total of 3575 participants underwent randomization, of whom 3573 received at least one dose of M72/AS01 CONCLUSIONS: Among adults infected with